These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23566417)

  • 1. αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma.
    Ducassou A; Uro-Coste E; Verrelle P; Filleron T; Benouaich-Amiel A; Lubrano V; Sol JC; Delisle MB; Favre G; Ken S; Laprie A; De Porre P; Toulas C; Poublanc M; Cohen-Jonathan Moyal E
    Eur J Cancer; 2013 Jun; 49(9):2161-9. PubMed ID: 23566417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB.
    Monferran S; Skuli N; Delmas C; Favre G; Bonnet J; Cohen-Jonathan-Moyal E; Toulas C
    Int J Cancer; 2008 Jul; 123(2):357-364. PubMed ID: 18464290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
    Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
    J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
    Weller M; Nabors LB; Gorlia T; Leske H; Rushing E; Bady P; Hicking C; Perry J; Hong YK; Roth P; Wick W; Goodman SL; Hegi ME; Picard M; Moch H; Straub J; Stupp R
    Oncotarget; 2016 Mar; 7(12):15018-32. PubMed ID: 26918452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.
    Usul Afsar C; Sahin B; Gunaldi M; Kılıc Bagir E; Gumurdulu D; Burgut R; Erkisi M; Kara IO; Paydas S; Karaca F; Ercolak V
    Int J Clin Exp Pathol; 2015; 8(9):9760-71. PubMed ID: 26617686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
    J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
    J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease.
    Lustig R; Mikkelsen T; Lesser G; Grossman S; Ye X; Desideri S; Fisher J; Wright J;
    Neuro Oncol; 2008 Dec; 10(6):1004-9. PubMed ID: 18725460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
    Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
    Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.
    Skuli N; Monferran S; Delmas C; Favre G; Bonnet J; Toulas C; Cohen-Jonathan Moyal E
    Cancer Res; 2009 Apr; 69(8):3308-16. PubMed ID: 19351861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subventricular zones: new key targets for glioblastoma treatment.
    Khalifa J; Tensaouti F; Lusque A; Plas B; Lotterie JA; Benouaich-Amiel A; Uro-Coste E; Lubrano V; Cohen-Jonathan Moyal E
    Radiat Oncol; 2017 Apr; 12(1):67. PubMed ID: 28424082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme.
    Moyal EC; Laprie A; Delannes M; Poublanc M; Catalaa I; Dalenc F; Berchery D; Sabatier J; Bousquet P; De Porre P; Alaux B; Toulas C
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1396-401. PubMed ID: 17570606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy.
    Wang W; Zhu NL; Chua J; Swenson S; Costa FK; Schmitmeier S; Sosnowski BA; Shichinohe T; Kasahara N; Chen TC
    J Neurosurg; 2005 Dec; 103(6):1058-66. PubMed ID: 16381193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
    Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY
    J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.
    Lamfers ML; Grill J; Dirven CM; Van Beusechem VW; Geoerger B; Van Den Berg J; Alemany R; Fueyo J; Curiel DT; Vassal G; Pinedo HM; Vandertop WP; Gerritsen WR
    Cancer Res; 2002 Oct; 62(20):5736-42. PubMed ID: 12384532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation.
    Anderson HJ; Galileo DS
    Cell Oncol (Dordr); 2016 Jun; 39(3):229-42. PubMed ID: 26883759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of integrins αvβ3 and αvβ5 and their ligands in primary and secondary central nervous system neoplasms.
    Mittelbronn M; Warth A; Meyermann R; Goodman S; Weller M
    Histol Histopathol; 2013 Jun; 28(6):749-58. PubMed ID: 23238957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article.
    Muragaki Y; Maruyama T; Iseki H; Tanaka M; Shinohara C; Takakura K; Tsuboi K; Yamamoto T; Matsumura A; Matsutani M; Karasawa K; Shimada K; Yamaguchi N; Nakazato Y; Sato K; Uemae Y; Ohno T; Okada Y; Hori T
    J Neurosurg; 2011 Aug; 115(2):248-55. PubMed ID: 21568657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.